Italian Network for Research in Urologic Oncology
Joined May 2021
- Tweets256
- Following258
- Followers309
- Likes574
Meet-URO retweeted
EV + Pembrolizumab in Collecting Duct and Renal Medullary Carcinoma: Preliminary Results from the REPRINT – MeetURO 4/25 Trial. Presented by @g_procopio_ @IstTumori. #ESMO26 written coverage by @rksayyid @UAUrology > bit.ly/4zlWowA #KidneyCancer #RCC @myESMO
Meet-URO retweeted
P+EV shows promising activity in collecting duct and renal medullary carcinomas! 🧬
We’ve worked hard to get here, and the road is still long.
Proud of our team! 👏
@g_procopio_ @elena_verzoni
#ESMO26 #GUOncology #RareCancers
Meet-URO retweeted
Great work! New target are coming for mCDC
#renalcellcarcinoma
New data in @ESMO_Open : among 59 centrally reviewed collecting duct carcinoma cases, Trop-2 was expressed in 89% and Nectin-4 in 41%, supporting further investigation of antibody-drug conjugates in this rare disease.
doi.org/10.1016/j.esmoop.202…
#KidneyCancer #RareCancer
Meet-URO retweeted
Insightful presentation by @g_procopio_! REPRINT: EV + pembrolizumab produced responses in 2/9 evaluable patients, both with a renal medullary carcinoma subtype; none in collecting duct carcinoma. Early data in rare kidney cancers! #ESMO26 @oncoalert @myESMO
Meet-URO retweeted
@IstTumori è al 4° posto in Italia nella classifica Italy’s Best Employers 2027 e al 1° posto nel settore Sanità e Ambito Sociale.
Un riconoscimento che premia le persone che ogni giorno fanno l’Istituto.
#BestEmployers2027
L'intera classifica:
corriere.it/buone-notizie/26…
How are drug–drug interactions managed in #ProstateCancer?
Our international survey in collabs with ONCOassist reveals gaps in DDI management, highlighting the need for reliable tools & multidisciplinary collaboration.
doi.org/10.1093/oncolo/oyag3…
Real world data about bone metastases in metastatic renal cell carcinoma (data from Meet-URO 33).
sciencedirect.com/science/ar…
Meet-URO retweeted
🎬 "Il Filo di Arianna - Un viaggio nel labirinto del tumore del rene" è stato presentato alla Mostra del Cinema di Venezia.
Presente per il nostro Istituto Giuseppe Procopio, Direttore di Oncologia Medica Genitourinaria, intervenuto al talk con i protagonisti.
#INT #Oncologia
Meet-URO retweeted
📢 The results of the first @Fondaz_Veronesi & FICOG call for independent clinical research in #PancreaticCancer are out!
share.google/iZp5RL3RI4LVWI5…
A joint initiative supporting innovative research to address unmet clinical needs and improve patient care.
Meet-URO retweeted
Fonte: Fondazione Umberto Veronesi
share.google/aBM1AH9jPli7Pup…
Pubblicati I risultati del bando Fondazione Umberto Veronesi e Ficog sul trattamento del tumore del pancreas
Meet-URO retweeted
New insights into Lynch syndrome-associated urothelial cancer: molecular profiling reveals frequent #FGFR3 alterations, highlighting potential therapeutic vulnerabilities in this rare disease.
Full article: doi.org/10.1007/s10689-026-0…
#LynchSyndrome #UrothelialCancer
Meet-URO retweeted
Il Filo di Arianna, a journey through the maze of #KidneyCancer comes to the 83rd Venice International Film Festival for a special screening and talk with the protagonists.
📅 September 10 | 6 PM
📍 Giffoni Innovation Hub, Venice Lido
#Venezia26 #CancerAwareness #RCC
🤖 Made with AI
Meet-URO retweeted
Look at our last @meeturoIT review 📌
Can #biomarkers guide first-line treatment in #mRCC?
Our systematic review explores molecular & circulating biomarkers across phase III trials. Promising signals are emerging, but no validated biomarker yet guides treatment selection.
#PrecisionOncology
doi.org/10.1007/s10555-026-1…
Meet-URO retweeted
Can #biomarkers guide first-line treatment in #mRCC?
Our systematic review explores molecular & circulating biomarkers across phase III trials. Promising signals are emerging, but no validated biomarker yet guides treatment selection.
#PrecisionOncology
doi.org/10.1007/s10555-026-1…
Can #biomarkers guide first-line treatment in #mRCC?
Our systematic review explores molecular & circulating biomarkers across phase III trials. Promising signals are emerging, but no validated biomarker yet guides treatment selection.
#PrecisionOncology
doi.org/10.1007/s10555-026-1…
Meet-URO retweeted
Online on #TAMO
👇🏽
With 1695 pts from 58 centers the Meet-URO 33–REGAL study shows an interesting real-world snapshot of #1L decision-making in #mRCC.
buff.ly/qKZSbw5
.
@gbanna74 @rebuzzisara @meeturoIT
Meet-URO retweeted
New Real World Evidence on Olaparib in mCRPC - Giuseppe Procopio
@g_procopio_
oncodaily.com/new-paper-aler…
Meet-URO retweeted
New real-world evidence on #Olaparib in #mCRPC: this global study lead by L.Incorvaia confirms clinical activity in HRR-altered tumors and highlights how specific #BRCA2 variant type and location may influence outcomes.
#ProstateCancer #ClinicalResearch
doi.org/10.1002/ijc.70679
